Cargando…
How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy
Chimeric antigen receptor (CAR) T cells have transformed the care for patients with hematologic malignancies. Patients treated with CAR T cells may experience cardiovascular and pulmonary complications, which primarily occur in the setting of cytokine release syndrome. In addition, many patients con...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329189/ https://www.ncbi.nlm.nih.gov/pubmed/36827628 http://dx.doi.org/10.1182/blood.2022017579 |